TOPLINE: Ustekinumab exhibited higher persistence rates as a second-line therapy than anti–tumour necrosis factor (anti-TNF) treatment in patients with Crohn’s disease. Clinical remission rates with ustekinumab improved progressively, reaching 100% by 5 years. METHODOLOGY: Researchers conducted this retrospective observational study of a prospective database to compare the persistence rates of ustekinumab as a second-line treatment ...
256 W Beech St P.O. Box 32 Harrison, Michigan, USA 48625
(989) 424-9929
austin@clippershipsandcaravans.com
Copyright © 2023 roenews2. All Rights Reserved
